We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TTP Labtech Acquires Assets from AssayMetrics
News

TTP Labtech Acquires Assets from AssayMetrics

TTP Labtech Acquires Assets from AssayMetrics
News

TTP Labtech Acquires Assets from AssayMetrics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TTP Labtech Acquires Assets from AssayMetrics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TTP Labtech has consolidated its position in the field with today’s announcement of the purchase of assets from AssayMetrics Limited, Cardiff, UK a leading company in fluorescence lifetime technology (FLT).

The acquisition enhances TTP Labtech’s new ameon™ system equipped with real-time decay curve analysis (RT-DCA), licensed from Fluorescence Innovations Inc (Minneapolis, US). The ameon represents the next generation of FLT reader technology providing a combination of speed, precision, and data quality that can be readily exploited in HTS workflows. 

“The development of the ameon reader introduces an exciting new dimension to FLT technology giving researchers a step-change in sample throughput and data quality,” said Dr Greg Gillispie, President of Fluorescence Innovations.

“Reception to ameon has been very positive with early feedback from beta-partners reporting superior tolerance to compound interference compared to established methodologies,” commented Dr Wayne Bowen, Chief Scientific Officer of TTP Labtech. “Increasing access to relevant instrumentation is revealing the true potential of FLT for cost critical assays to the screening community.”

Advertisement